genomic medicine | pharmaphorum

Tuesday 5 November 2024

Channels

Content type

Categories

Categories

Sort by

Order

genomic medicine

News

AZ builds in genomic medicine with $1bn Pfizer deal

AZ builds in genomic medicine with $1bn Pfizer deal

AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first

Digital

Abstract background - genome research. A look through a 24-well plate.

Investment fuels AI-driven development of breakthrough genom...

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets.

News

AZ_Alexion

AstraZeneca pays record 660% premium for gene editing compan...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Print

Sponsored

The power of R&D collaborations to improve outcomes in rare ...

Far more common than initially thought, rare disease treatments remain far too scarce.

Views & Analysis

The future of genomic medicine: can it fulfil its promises

The future of genomic medicine: can it fulfil its promises?

Last week geneticist Dr Charles Steward shared with us his experiences of

Views & Analysis

Nine-pharma-trends-for-2020

Nine pharma trends for 2020

Sarah Rickwood looks back at how pharma changed over the last decade and what this might mean for the industry in 2020.